Singapore biotech startup Mirxes in talks for US$1.2b SPAC listing in US
Add BT as a preferred source
Singapore
SINGAPORE biotech company Mirxes is in early talks to go public via a blank-cheque company affiliated with veteran private equity healthcare investor Fu Wei, according to people familiar with the matter.
A deal between Mirxes and Summit Healthcare Acquisition is set to value the combined entity at about US$1.2 billion, one of the people said. The special purpose acquisition company (SPAC) deal would feature a so-called private investment in public equity (PIPE), which involves a private placement of the company's common stock to its investors. A transaction could be reached by early next year, although talks might still fall apart.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
US-China rivalry and the Kindleberger Trap: Why inaction – not escalation – is the biggest risk
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Thai and Vietnamese farmers may stop planting rice because of the Iran war. Here’s why
Strengthening Asean’s economic resilience through RCEP’s 2027 review
